Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMV533
- Development stage
- Phase 1
- Lead developer
- Medicines for Malaria Venture
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MMV533 (formerly SAR441121) is a novel small molecule acylguanidine antimalarial compound developed through a collaboration between Medicines for Malaria Venture (MMV) and Sanofi. It is designed to treat uncomplicated malaria caused by *Plasmodium falciparum* by targeting the asexual blood stages of the parasite. MMV533 is characterized by a long elimination half-life of approximately 104–127 hours, which supports its potential as a component of simplified or single-dose combination therapies intended to manage emerging resistance to artemisinin and other partner drugs. The compound has demonstrated an acceptable safety and tolerability profile in Phase 1 clinical trials and is currently in early clinical development.
- Other names
- MMV533MMV-533MMV 533
02
Targets
AC (Adenylyl cyclase family)PfEHD (Plasmodium falciparum EHD protein)ATP1A (Sodium/potassium-transporting ATPase)
Beyond the preview
Go deeper on MMV533.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMV533.